Weight-Loss Drugs May Reduce Heart Damage After a Heart Attack, Study Finds
Medications designed to promote weight loss by mimicking glucagon-like peptide-1 (GLP-1) may also support limit additional heart damage after a heart attack. A new study led by researchers at the University of Bristol and University College London (UCL) found that these drugs could reduce the risk of serious complications that occur in up to half of heart attack patients.
The findings, published in Nature Communications on March 3, 2026, suggest that GLP-1 weight-loss drugs might offer a new strategy to improve recovery after a heart attack.
GLP-1 Drugs and Heart Health: Previous Research
Earlier research has already shown that GLP-1 weight-loss medications can lower the likelihood of major heart problems, regardless of a person’s existing health conditions or how much weight they lose while taking the drugs. A University of Bristol press release highlighted this benefit, noting the potential for improved outcomes even without significant weight loss.
Understanding the ‘No-Reflow’ Phenomenon
Scientists investigated how GLP-1 drugs protect the heart, focusing on the “no-reflow” phenomenon. This complication occurs in nearly half of all heart attack patients, where tiny blood vessels within the heart muscle remain narrowed even after the main artery is cleared during emergency medical treatment. This results in blood being unable to reach certain parts of the heart tissue, increasing the risk of death or hospital admission for heart failure within a year of a heart attack.
How GLP-1 Drugs Improve Blood Flow
The research team built upon previous operate demonstrating that small contractile cells called pericytes constrict coronary capillaries during ischemia – a condition where the heart muscle is deprived of oxygen-rich blood. The new study explored whether GLP-1 drugs could counteract this process and reopen the blocked blood vessels.
Experiments revealed that GLP-1 drugs improve blood flow in the heart after a heart attack by activating potassium channels. This activation relaxes pericytes, allowing the constricted blood vessels to widen and enabling more effective blood flow to heart tissue, thereby lowering the chance of additional damage.
A Potential Repurposing Opportunity
Professor David Attwell, Jodrell Professor of Physiology at UCL, and the study’s co-lead, noted the potential for repurposing existing drugs. “With an increasing number of similar GLP-1 drugs now being used in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our findings highlight the potential for these existing drugs to be repurposed to treat the risk of ‘no-reflow’ in heart attack patients, offering a potentially life-saving solution,” he said. UCL News reported.
Dr. Svetlana Mastitskaya, Senior Lecturer in Cardiovascular Regenerative Medicine at Bristol Medical School: Translational Health Sciences (THS) and the study’s lead author, is funded by the British Heart Foundation.